Dr. Cadavid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
61 N Beacon St
Boston, MA 02134Phone+1 617-599-0755
Education & Training
MedStar Health/Georgetown University HospitalResidency, Neurology, 1995 - 1998
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1994 - 1995
Pontifical Xavierian UniversityClass of 1991
Certifications & Licensure
MA State Medical License 2013 - 2026
NJ State Medical License 1999 - 2009
DC State Medical License 1998 - 2000- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- 4 citationsSafety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, Doris G Leung, Jeffrey M Statland
The Lancet. Neurology. 2024-05-01 - The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study.Isha Jalnapurkar, Jean A Frazier, Mark Roth, David M Cochran, Ann Foley
Journal of Neurodevelopmental Disorders. 2022-12-09 - 11 citationsQuantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.Michelle L Mellion, Per Widholm, Markus Karlsson, André Ahlgren, Rabi Tawil
Neurology. 2022-08-30
Press Mentions
Verge Genomics to Incorporate Emerald Digital Health Technology into Its ALS Phase 1b Proof-of-Concept Clinical TrialMay 24th, 2023- X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021June 11th, 2021
- Immune Regulation Makes Peter Greenleaf Chairman and Assembles a Quintet of New Execs; Bob Coughlin Moves on from MassBio to JLLDecember 18th, 2020
- Join now to see all
Grant Support
- Protective Role Of Interleukin 10 In NeuroborreliosisNational Institute Of Neurological Disorders And Stroke2008–2009
- Borrelia Lipoproteins With The Cerebral MicrocirculationNational Institute Of Neurological Disorders And Stroke2006–2007
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
